177Lu-DOTATATE Salvage Therapy in Rapidly Progressing Neuroendocrine Tumor With Poor Performance Status-Reference-Cited by-同舟云学术

177Lu-DOTATATE Salvage Therapy in Rapidly Progressing Neuroendocrine Tumor With Poor Performance Status

Published:2024-03-18 Issue:6 Volume:49 Page:561-563
ISSN:1536-0229
Container-title:Clinical Nuclear Medicine
language:en
Short-container-title:Clin Nucl Med

Author:

Aggarwal Piyush¹,Kumar Ajay¹,Sood Ashwani¹,Walia Rama²,Bhadada Sanjay Kumar²,Mittal Bhagwant Rai¹

Affiliation:

1. Department of Nuclear Medicine

2. Department of Endocrinology, Post Graduate Institute of Medical Education and Research (PGIMER), Sector 12, Chandigarh 160012, India.

Abstract

Abstract Peptide receptor radionuclide therapy (PRRT) has shown to be effective and safe in metastatic gastroenteropancreatic and nongastroenteropancreatic neuroendocrine tumors. However, the selection criteria for PRRT are restricted to patients with good performance status (Eastern Cooperative Oncology Group score ≤2 or Karnofsky performance score ≥60). This denies many patients with adequate somatostatin receptor expression and biochemical profiles from the beneficial effects of PRRT on the quality of life, daily function, and overall survival. The 2 cases highlight the favorable response of PRRT in patients with metastatic neuroendocrine tumor having a very poor performance status initially.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference9 articles.

1. Phase 3 trial of 177Lu-DOTATATE for midgut neuroendocrine tumors;N Engl J Med,2017

2. A clinical guide to peptide receptor radionuclide therapy with 177Lu-DOTATATE in neuroendocrine tumor patients;Cancers (Basel),2022

3. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours;Eur J Nucl Med Mol Imaging,2014

4. Indications of peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic and pulmonary neuroendocrine tumors: an updated review;J Clin Med,2021

5. Toxicity and response criteria of the Eastern Cooperative Oncology Group;Am J Clin Oncol,1982